The global liver cancer drug market size is anticipated to reach USD 9.81 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 17.9% from 2025 to 2030. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75–90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights

• The targeted therapy segment held the largest market revenue share of 53.1% in 2024 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
• Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 38.2% revenue share in 2024. HCC Is the most common type of primary liver cancer.
• Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.7% in 2024.
• North America liver cancer drug market held a revenue share of 38.7% in 2024.

Liver Cancer Drug Market Segmentation

Grand View Research has segmented the global liver cancer drug market report based on therapy, type, distribution channel and region:

Liver Cancer Drug Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Others

Liver Cancer Drug Type Outlook (Revenue, USD Million, 2018 - 2030)

• Hepatocellular Carcinoma
• Cholangio Carcinoma
• Hepatoblastoma
• Others

Liver Cancer Drug Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies 

Liver Cancer Drug Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Key Players in the Liver Cancer Drug Market

• Exelixis, Inc.
• Merck KGaA
• Eisai Co., Ltd.
• Bristol-Myers Squibb Company
• Thermo Fisher Scientific Inc.
• Pfizer Inc.
• Eli Lilly and Company
• Hoffmann-La Roche Ltd
• Novartis AG
• Bayer AG

Order a free sample PDF of the Liver Cancer Drug Market Intelligence Study, published by Grand View Research.